Infliximab induced endophthalmitis in a patient of fistulizing Crohn’s disease

  • Rashi Kochhar
  • Vishali Gupta
  • Usha Dutta
  • Kartar Singh
  • Rakesh Kochhar
Letter

References

  1. 1.
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s diseases. N Engl J Med. 1999;340:1398–405.PubMedCrossRefGoogle Scholar
  2. 2.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease; the Mayo Clinic experience in 500 patients. Gastroenterology. 2004;126:19–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Naranjo A, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Agarwal PK, Gallaghar M, Murphy E, Virdi M. Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker. Indian J Ophthalmol. 2007;55:230–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Anonymous. Adalimumab/etanercept/infliximab: endophthalmitis leading to vision loss: 3 case reports. Reactions Weekly July, 12, 2008.Google Scholar
  7. 7.
    Schiedler V, Scott IU, Flynnir HW Jr, Davis JL, Benz MS, Miller D. Culture-proven endogenous endophlhalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol. 2004;137:725–31.PubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2011

Authors and Affiliations

  • Rashi Kochhar
    • 1
  • Vishali Gupta
    • 2
  • Usha Dutta
    • 1
  • Kartar Singh
    • 1
  • Rakesh Kochhar
    • 1
  1. 1.Department of GastroenterologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  2. 2.Department of OphthalmologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations